| PULMONX CORP. DL-,001 |
| USA |
| Gesundheit |
| US7458481014 / A2P1AF |
| 4NI (Frankfurt) / LUNG (NASDAQ) |
| FRA:4NI, ETR:4NI, 4NI:GR, NASDAQ:LUNG |
| - |
| https://pulmonx.com/ |
|
Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for severe emphysema and other obstructive lung diseases. The company’s core offering is the Zephyr Endobronchial Valve, a bronchoscopic implant designed t..
>Volltext.. |
| 97.2 Mio. EUR |
| 100.26 Mio. EUR |
| 79.73 Mio. EUR |
| -34.41 Mio. EUR |
| -38.22 Mio. EUR |
| -0.91 EUR |
| 50.61 Mio. EUR |
| 47.55 Mio. EUR |
| - |
| 2.55 |
| -3.15% |
| 25.02% |
| - |
| - |
| - |
| - |
| PULMONX |
| 30.10.26 |
|
||||
|